SEARCH

SEARCH BY CITATION

References

  • 1
    Parikh AA,Ellis LM. The vascular endothelial growth factor family and its receptors. Hematol Oncol Clin North Am. 2004; 18: 951971, vii.
  • 2
    Ferrara N,Gerber HP,LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9: 669676.
  • 3
    Srivastava A,Ralhan R,Kaur J. Angiogenesis in cutaneous melanoma: pathogenesis and clinical implications. Microsc Res Tech. 2003; 60: 208224.
  • 4
    Graells J,Vinyals A,Figueras A, et al. Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol. 2004; 123: 11511161.
  • 5
    Streit M,Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene. 2003; 22: 31723179.
  • 6
    Demirkesen C,Buyukpinarbasili N,Ramazanoglu R,Oguz O,Mandel NM,Kaner G. The correlation of angiogenesis with metastasis in primary cutaneous melanoma: a comparative analysis of microvessel density, expression of vascular endothelial growth factor and basic fibroblastic growth factor. Pathology. 2006; 38: 132137.
  • 7
    Salven P,Heikkila P,Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer. 1997; 76: 930934.
  • 8
    Ugurel S,Rappl G,Tilgen W,Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol. 2001; 19: 577583.
  • 9
    Oku T,Tjuvajev JG,Miyagawa T, et al. Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res. 1998; 58: 41854192.
  • 10
    Lev DC,Onn A,Melinkova VO, et al. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol. 2004; 22: 20922100.
  • 11
    Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001; 7: 987989.
  • 12
    Nor JE,Christensen J,Mooney DJ,Polverini PJ. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol. 1999; 154: 375384.
  • 13
    Masood R,Cai J,Zheng T,Smith DL,Hinton DR,Gill PS. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood. 2001; 98: 19041913.
  • 14
    Lacal PM,Failla CM,Pagani E, et al. Human melanoma cells secrete and respond to placenta growth factor and vascular endothelial growth factor. J Invest Dermatol. 2000; 115: 10001007.
  • 15
    Ferrara N,Hillan KJ,Gerber HP,Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004; 3: 391400.
  • 16
    Varker KA,Biber JE,Kefauver C, et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol. 2007; 14: 23672376.
  • 17
    Sandler A,Gray R,Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 25422550.
  • 18
    Kabbinavar FF,Hambleton J,Mass RD,Hurwitz HI,Bergsland E,Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005; 23: 37063712.
  • 19
    Giantonio BJ,Catalano PJ,Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200 [abstract]. J Clin Oncol. 2005; 23: 1s.
  • 20
    Middleton MR,Grob JJ,Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000; 18: 158166.
  • 21
    Hodi FS,Soiffer RJ,Clark J,Finkelstein DM,Haluska FG. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol. 2002; 25: 283286.
  • 22
    Zimpfer-Rechner C,Hofmann U,Figl R, et al. Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res. 2003; 13: 531536.
  • 23
    Agarwala SS,Keilholz U,Hogg D, et al. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma [abstract]. J Clin Oncol. 2007; 25(18 suppl): 8510.
  • 24
    Rao RD,Holtan SG,Ingle JN, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer. 2006; 106: 375382.
  • 25
    Simon R. Optimal 2-stage designs for phase II clinical trial. Control Clin Trials. 1989; 10: 110.
  • 26
    Duffy DE,Santner TJ. Confidence intervals for binomial parameter based on multistage tests. Biometrics. 1987; 43: 8193.
  • 27
    Kaplan EL,Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 28
    Scappaticci FA,Skillings JR,Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007; 99: 12321239.
  • 29
    Korn EL,Liu PY,Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008; 26: 527534.
  • 30
    Siegel AB,Cohen EI,Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008; 26: 29922998.
  • 31
    Vacca A,Ribatti D,Iurlaro M, et al. Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res. 2002; 11: 103118.
  • 32
    Belani CP,Barstis J,Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol. 2003; 21: 29332939.
  • 33
    Ng SS,Figg WD,Sparreboom A. Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res. 2004; 64: 821824.
  • 34
    Ng SS,Sparreboom A,Shaked Y, et al. Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel. Clin Cancer Res. 2006; 12: 43314338.
  • 35
    Nyman DW,Campbell KJ,Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol. 2005; 23: 77857793.